跳转至内容
Merck
CN

D2763

双氢麦角胺 甲磺酸盐

powder

登录 查看组织和合同定价。

选择尺寸

关于此项目

经验公式（希尔记法）:
C33H37N5O5 · CH4O3S
化学文摘社编号:
6190-39-2
分子量:
679.78
NACRES:
NA.77
PubChem Substance ID:
24277913
UNSPSC Code:
12352200
EC Number:
228-235-6
MDL number:
MFCD00058615

主要文件

查看所有文档
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助？我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

InChI key

ADYPXRFPBQGGAH-WVVAGBSPSA-N

InChI

1S/C33H37N5O5.CH4O3S/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32;1-5(2,3)4/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39);1H3,(H,2,3,4)/t21-,23?,25-,26+,27+,32-,33+;/m1./s1

SMILES string

CS(O)(=O)=O.[H][C@@]12Cc3c[nH]c4cccc(C1C[C@H](CN2C)C(=O)N[C@]5(C)O[C@]6(O)N([C@@H](Cc7ccccc7)C(=O)N8CCC[C@@]68[H])C5=O)c34

form

powder

color

white

solubility

methanol: 21 mg/mL, 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 5.45 mg/mL, H2O: insoluble

Gene Information

human ... DRD2(1813)

正在寻找类似产品? 访问 产品对比指南

Biochem/physiol Actions

血管羟色胺受体激动剂；α-肾上腺素和多巴胺 D2 受体部分激动剂；血管收缩剂。
Vascular serotonin receptor agonist; vasoconstrictor.

pictograms

Exclamation mark
GHS07

signalword

Warning

Hazard Classifications

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

新产品
此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number
097K1459
105F0105

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Nancy E Kelley et al.
Headache, 52(1), 114-128 (2012-01-04)
To review and analyze published reports on the acute treatment of migraine headache with triptans, dihydroergotamine (DHE), and magnesium in emergency department, urgent care, and headache clinic settings. MEDLINE was searched using the terms "migraine" and "emergency," and "therapy" or
D Kellerman et al.
Cephalalgia : an international journal of headache, 32(2), 150-158 (2011-12-17)
Dihydroergotamine (DHE), a proven migraine treatment, currently has product labeling warning against concomitant use of CYP3A4 inhibitors because of potential drug interactions. However, no reported studies of such interactions with DHE administered by any route are available. The pharmacokinetics (PK)
Shashidhar Kori et al.
Clinical therapeutics, 34(9), 1920-1928 (2012-08-25)
MAP0004 is an orally inhaled investigational drug containing dihydroergotamine (DHE). Although DHE has been used for 60 years with no reported cardiac arrhythmias, a thorough QT study had not previously been performed with DHE. The objective of this study was
Bruno A Marichal-Cancino et al.
European journal of pharmacology, 692(1-3), 69-77 (2012-07-31)
It has been suggested that during a migraine attack trigeminal nerves release calcitonin gene-related peptide (CGRP), producing central nociception and vasodilatation of cranial arteries, including the extracranial branches of the external carotid artery. Since trigeminal inhibition may prevent this vasodilatation
Anick Bérard et al.
Headache, 52(7), 1085-1093 (2012-05-23)
Dihydroergotamine (DHE) is perceived to be associated with a higher risk of adverse pregnancy events, but it has significantly less vasoconstrictive and uterotonic effects compared with ergotamine, and has demonstrated no teratogenic effect in animals. The objectives of this study
查看所有相关文献

相关内容

Product Information Sheet - D2763

Product Information Sheet

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持